← brief for 2026-09-21 · Slowing decline

Comparative Effects of Dapagliflozin versus Linagliptin as Add-on to Metformin on Glycemic and Renal Outcomes: A 24-Week Non-Randomized Prospective Observational Cohort Study in Indian Patients with Type 2 Diabetes Mellitus and Stage 2-3a chronic kidney disease

Preprint C Not peer reviewed Observational

Key takeaways

This study looked at two diabetes drugs, dapagliflozin and linagliptin, in people with early kidney disease. It tracked how these drugs affected blood sugar and kidney health over 24 weeks. Because the researchers did not randomly assign patients to groups, this shows a link but not proof of cause. The results are not yet peer-reviewed.

Who did this work

Khanna¹ S · Malik² M · Malik B · Ahmad R

Source

Preprint · Europe PMC, CKD · 2026-09-21
https://doi.org/10.21203/rs.3.rs-10735039/v1